MedTrace Logo

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

NCT03521895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2020-01-10

No results posted yet for this study

Summary

The aim of this integrated analysis is to describe the effectiveness of Eylea in an integrated pooled analysis using existing individual patient data of two non-interventional studies RAINBOW and PERSEUS.

The primary objective of this integrated analysis is to describe the effectiveness of Eylea on the mean change from baseline in visual acuity (VA) at 12 months in Wet age-related macular degeneration (wAMD) treatment naïve patients.

Conditions

  • Macular Degeneration

Interventions

DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Patients observed with regular and irregular treatment course

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03521895 on ClinicalTrials.gov